Lee Sung sold $266K of CYTK
Lee Sung (EVP, Chief Financial Officer) sold 3,134 shares of CYTOKINETICS INC (CYTK) at $85.00 ($0.27M total) on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Confirms an open-market sale executed under a pre-arranged Rule 10b5-1 plan; typically limited incremental information for valuation.
Market read
Traders may monitor for patterns in insider activity, but this specific disclosure is unlikely to drive a major repricing by itself.
What to watch
The filing doesn’t disclose reasons for sale, and the post-transaction holdings (63,221 shares) may matter more than the single-day tranche size for interpreting insider behavior.
Background
The article is an SEC Form 4 insider transaction by CYTOKINETICS CFO Lee Sung.
Ticker impact
CFO Lee Sung filed a Form 4 selling 3,134 CYTK shares at $85 on 2026-06-29 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this sale; any impact would be short-lived and sentiment-driven.
The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan; such transactions are typically less informative than unscheduled sales.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because it’s a 10b5-1 plan, the sale may reflect scheduled diversification rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerCYTOKINETICS INC
Subject of the Form 4 insider transaction disclosure.
- insiderLee Sung
EVP, Chief Financial Officer who sold shares.
